全球神經生物標記市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計神經生物標記市場將從 2025 年的 111.8 億美元成長到 2034 年的 289.8 億美元，2026 年至 2034 年的複合年成長率為 11.16%。

隨著研究機構和製藥公司日益重視精準醫療，神經生物標記市場正在快速發展。在阿茲海默症、帕金森氏症和多發性硬化症等複雜的神經系統疾病中，生物標記在早期診斷、藥物反應監測和治療策略制定方面發揮著越來越重要的作用。隨著對臨床試驗和分子診斷平台投入的不斷增加，以及基因組學、蛋白質組學和影像技術的融合，該領域有望進一步發展。這種發展不僅將提高診斷準確性，還將為個人化醫療鋪路，從而顯著改善患者的治療效果。

數位健康工具正進一步推動對神經生物標記的需求，尤其是在人工智慧和機器學習的幫助下，能夠快速檢驗複雜的資料集。穿戴式裝置和數位診斷技術正在收集認知功能和神經生理參數的即時數據，這些數據與已驗證的生物標記相結合，可實現全面的疾病監測。在藥物研發過程中，生物標記正擴大被納入試驗通訊協定，以識別最有可能對標靶治療反應的患者亞群，從而加快核准流程並降低藥物研發的失敗率。

未來幾年，我們預計生技公司、診斷公司和醫療保健系統之間將進行更深入的跨學科合作，從而推動生物標記檢驗和商業化的擴展。隨著監管機構完善其生物標記合格框架，可重複性和臨床效用將變得日益重要。此外，向腦脊髓液液態生物檢體和血液檢測等微創檢測方法的轉變將提高全球神經系統生物標記檢測的可及性和擴充性。這種創新與臨床整合的融合正在將該市場打造為未來神經退化性疾病管理的基礎。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球神經生物標記市場：依產品類型分類

• 市場分析、洞察與預測
• 蛋白質體學生物標記
• 基因生物標記
• 代謝生物標記
• 診斷影像
• 其他類型的生物標記

第5章 全球神經生物標記市場：依疾病類型分類

• 市場分析、洞察與預測
• 阿茲海默症
• 帕金森氏症
• 泛自閉症障礙
• 癲癇
• 其他疾病

第6章 全球神經生物標記市場：依最終用途分類

• 市場分析、洞察與預測
• 醫院和診所
• 研究所
• 生物製藥公司
• 其他最終用戶

第7章 全球神經生物標記市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Abbott Laboratories
  • ACOBIOM
  • Alseres Pharmaceuticals Inc
  • Banyan Biomarkers Inc
  • Bio-Rad Laboratories Inc
  • DiaGenic ASA
  • Johnson & Johnson
  • Merck KGaA
  • QIAGEN NV
  • Quanterix Corporation
  • Rules-Based Medicine Inc
  • Thermo Fisher Scientific Inc

The Neurological Biomarkers Market size is expected to reach USD 28.98 Billion in 2034 from USD 11.18 Billion (2025) growing at a CAGR of 11.16% during 2026-2034.

The neurological biomarkers market is advancing rapidly as research institutions and pharmaceutical developers intensify their focus on precision medicine. Biomarkers are becoming instrumental in early diagnosis, drug response monitoring, and therapeutic decision-making for complex neurological disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. With rising investments in clinical trials and molecular diagnostic platforms, the sector is set to benefit from the integration of genomics, proteomics, and imaging technologies. This evolution will not only enhance diagnostic accuracy but also open pathways for personalized interventions, significantly improving patient outcomes.

Digital health tools are further reinforcing the demand for neurological biomarkers, particularly as artificial intelligence and machine learning enable faster interpretation of complex datasets. Wearable devices and digital diagnostics are capturing real-time data on cognitive function and neurophysiological parameters, which can be linked with validated biomarkers for comprehensive disease monitoring. Pharmaceutical pipelines are increasingly embedding biomarkers into trial protocols to identify patient subgroups most likely to respond to targeted therapies, accelerating approval timelines and reducing attrition rates in drug development.

The coming years are expected to witness deeper cross-sector collaborations between biotech firms, diagnostic companies, and healthcare systems to expand biomarker validation and commercialization. As regulatory bodies refine frameworks for biomarker qualification, greater emphasis will be placed on reproducibility and clinical utility. Moreover, the shift toward minimally invasive testing methods, such as liquid biopsies using cerebrospinal fluid or blood-based assays, will drive accessibility and scalability of neurological biomarker testing worldwide. This convergence of innovation and clinical integration positions the market as a cornerstone for the future of neurodegenerative disease management.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• Proteomic Biomarkers
• Genomic Biomarkers
• Metabolomic Biomarkers
• Imaging
• Other Biomarker Types

By Disease Type

• Alzheimer's Disease
• Parkinson's Disease
• Autism Spectrum Disorders
• Epilepsy
• Other Diseases

By End Use

• Hospitals and Clinics
• Research Laboratories
• Biopharmaceutical Companies
• Other End Users

COMPANIES PROFILED

• Abbott Laboratories, ACOBIOM, Alseres Pharmaceuticals Inc, Banyan Biomarkers Inc, BioRad Laboratories Inc, DiaGenic ASA, Johnson Johnson, Merck KGaA, QIAGEN NV, Quanterix Corporation, RulesBased Medicine Inc, Thermo Fisher Scientific Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Proteomic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Genomic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Metabolomic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Imaging Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Biomarker Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Type
• 5.2. Alzheimer's Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Parkinson's Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Autism Spectrum Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Epilepsy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Hospitals and Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Research Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product Type
  • 7.2.2 By Disease Type
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product Type
  • 7.3.2 By Disease Type
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product Type
  • 7.4.2 By Disease Type
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product Type
  • 7.5.2 By Disease Type
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product Type
  • 7.6.2 By Disease Type
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL NEUROLOGICAL BIOMARKERS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Abbott Laboratories
  • 9.2.2 ACOBIOM
  • 9.2.3 Alseres Pharmaceuticals Inc
  • 9.2.4 Banyan Biomarkers Inc
  • 9.2.5 Bio-Rad Laboratories Inc
  • 9.2.6 DiaGenic ASA
  • 9.2.7 Johnson & Johnson
  • 9.2.8 Merck KGaA
  • 9.2.9 QIAGEN N.V
  • 9.2.10 Quanterix Corporation
  • 9.2.11 Rules-Based Medicine Inc
  • 9.2.12 Thermo Fisher Scientific Inc